Table 3. Clinical characteristics of patients with non-Elizabethkingia bacteremia.
| Case/ strain no. | Sex | Age | Underlying diseases | Diagnosis | Community- or hospital-acquired | No. of positive blood cultures (concomitant isolates) | Other culture-positive specimens | Treatment + removal of catheter | Complications + outcome |
|---|---|---|---|---|---|---|---|---|---|
| Potentially novel Chryseobacterium species | |||||||||
| C13 | M | 64 | Metastatic pancreatic carcinoma, sepsis | Postmortem pseudobacteremia | NA | 1 | None | NA | Died (non-attributable) |
| C15 | M | 68 | Head injury | Pseudobacteremia | NA | 1 (Acinetobacter sp., Enterococcus faecium) | No | Amoxicillin-clavulanate | Survived |
| Chryseobacterium arthrosphaerae | |||||||||
| C1 | M | 82 | HT, gout, BPH, bilateral hydronephrosis and hydroureter | Nosocomial bacteremia | HA | 1 | None | Piperacillin-tazobactam, then levofloxacin | Survived |
| C2 | F | 48 | Stage IV DLBC lymphoma | Catheter-related bacteremia, neutropenic fever | HA | 6 (Klebsiella pneumoniae, Acinetobacter baumanii) | Central catheter | Imipenem-cilastatin and amikacin | Septic shock, survived |
| C9 | M | 56 | COPD, pneumothorax | Nosocomial bacteremia | HA | 1 | None | Ticarcillin-clavulanate, levofloxacin | Survived |
| Chryseobacterium gallinarum | |||||||||
| C14 | M | 1 | Cow milk allergy | Nosocomial bacteremia | HA | 1 | None | Piperacillin-tazobactam | Survived |
| Chryseobacterium hominis | |||||||||
| C8 | F | 76 | DM, HT, CVA, CHF, AAA, PVD, hyperlipidemia | Pseudobacteremia | NA | 1 | None | None | Survived |
| C12 | F | 51 | AML | Neutropenic fever | HA | 1 (Moraxella sp.) | None | Piperacillin-tazobactam, vancomycin | Survived |
| Chryseobacterium indologenes | |||||||||
| C3 | F | 58 | Hyperlipidemia, IgA nephropathy, Multiple myeloma | Pseudobacteremia | NA | 1 (Stenotrophomonas maltophila, Commamonas sp,, Ralstonia sp.) | None | Levofloxacin, piperacillin-tazobactam | Survived |
| C4 | F | 49 | DM, CRF, bilateral hydronephrosis, perinephric and psoas abscess | Pseudobacteremia | NA | 1 (Enterococcus facaelis, A. baumanii, Streptococcus mitis) | None | Cefuroxime, ampicillin, levofloxacin | Survived |
| C5 | M | 78 | HT, gout, CA caecum with metastases, thyroidectomy | Pseudobacteremia | NA | 1 (A. baumanii) | None | Amoxicillin-clavulanate, ciprofloxacin | Survived |
| C6 | F | 57 | CA rectum, mania, small bowel obstruction | Pseudobacteremia | NA | 1 (E. facaelis, A. baumanii) | None | Amoxicillin-clavulanate | Survived |
| C7 | M | 84 | HT, AF,CRHD, CVA, gout, BPH COPD | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| C10 | F | 56 | Acute encephalopathy, aspiration pneumonia, sepsis | Postmortem pseudobacteremia | NA | 1 (Pseuodmonas putida, Bacillus sp., CNS, MSSA, non-hemolytic Streptococcus) | None | NA | Died (non-attributible) |
| Chryseobacterium taihuense | |||||||||
| C11 | M | 85 | DM, DU, BPH | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| Flavobacterium lindanitolerans | |||||||||
| F1 | F | 30 | SLE, lupus nephritis | Nosocomial (post-transfusion) bacteremia | HA | 1(Bacillus sp.) | None | Levofloxacin | Survived |
| Planobacterium taklimakanense | |||||||||
| P1 | M | 90 | CAD, COPD, DM, BPH | Primary bacteremia | CA | 1 | None | Ceftriaxone | Survived |
| P2 | M | 1d | RDS, congenital pneumonia | Pseudobacteremia | NA | 1 | None | Penicillin and netilmicin | Survived |
| P3 | F | 99 | COPD, CVA, intertrochanteric fracture | Pseudobacteremia | NA | 1 | None | Amoxicillin-clavulanate | Survived |
| P4 | M | 56 | COPD, BPH, PTB | Pseudobacteremia | NA | 1 | None | Levofloxacin | Survived |
| P5 | M | 52 | NPC, thyroidectomy, hypothyroidism | Nosocomial (post-transfusion) bacteremia | HA | 1 | None | Piperacillin-tazobactam | Survived |
| P6 | F | 1m | Sepsis, hypoglycemia | Pseudobacteremia | NA | 1 | None | Cefotaxime | Survived |
| Sphingobacterium daejeonense | |||||||||
| S1 | M | 94 | COPD, cor pulmonale, BPH, gout, Shy-Drager syndrome, CAD | Pseudobacteremia | NA | 1 (K. pneumoniae) | None | Cotrimoxazole | Survived |
| Potentially novel Weeksella-related species | |||||||||
| W1 | F | 18d | RSV pneumonia | Pseudobacteremia | NA | 1 | None | Ampicillin, netilmicin and erythromycin | Survived |
aAAA, abdominal aortic aneurysm; AF, atrial fibrillation; AML, acute myeloid leukemia; BPH, benign prostatic hyperplasia; CA, carcinoma; CA, community-acquired; CAD, coronary artery disease; CHF, congestive heart failure; CNS, coagulase-negative Staphylococcus; COPD; chronic obstructive pulmonary disease; CRF, chronic renal failure; CRHD, chronic rheumatic heart disease; CVA, cerebrovascular accident; DLBC, diffuse large B cell; DM, diabetes mellitus; DU, Duodenal ulcer; HA, hospital-acquired; HT, hypertension; MSSA, methicillin-sensitive Staphylococcus aureus; NA, not applicable; NPC, nasopharyngeal carcinoma; PTB, pulmonary tuberculosis; PVD, peripheral vascular disease; RDS, respiratory distress syndrome; RSV, respiratory syncytial virus; SLE, systemic lupus erythematosus.